Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $6.03 USD
Change Today -0.375 / -5.85%
Volume 1.2M
PGNX On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

progenics pharmaceuticals (PGNX) Snapshot

Open
$6.40
Previous Close
$6.41
Day High
$6.44
Day Low
$6.01
52 Week High
01/2/15 - $7.84
52 Week Low
05/9/14 - $3.10
Market Cap
419.9M
Average Volume 10 Days
903.7K
EPS TTM
$0.05
Shares Outstanding
69.6M
EX-Date
--
P/E TM
122.5x
Dividend
--
Dividend Yield
--
Current Stock Chart for PROGENICS PHARMACEUTICALS (PGNX)

progenics pharmaceuticals (PGNX) Related Businessweek News

No Related Businessweek News Found

progenics pharmaceuticals (PGNX) Details

Progenics Pharmaceuticals, Inc. develops medicines for oncology in the United States and internationally. The company’s primary clinical-stage product candidates include prostate specific membrane antigen (PSMA) antibody-drug conjugate, which has completed Phase II testing in chemotherapy-experienced patients and is ongoing second cohort in chemotherapy-naïve patients for the treatment of prostate cancer; 1404, a radio-labeled small molecule that has completed Phase II testing, as well as acts as an imaging agent to diagnose and detect prostate cancer; and Azedra, a radiotherapeutic product candidate, which is in Phase IIb registrational trial under special protocol assessment for the treatment of pheochromocytoma and paraganglioma. It also offers Relistor-subcutaneous injection for the treatment of opioid induced constipation (OIC) in advanced-illness patients receiving palliative care when laxative therapy has not been sufficient; and for treatment of OIC inpatients with non-cancer pain. In addition, the company develops Relistor-oral that has completed Phase III testing for the treatment of OIC. Further, it develops MIP-1095, a PSMA-targeted small molecule radiopharmaceutical that is in clinical development stage for the treatment of prostate cancer. The company has license agreement with Salix Pharmaceuticals, Inc. for the development and commercialization of Relistor worldwide; and with Amgen Fremont, Inc. to use its XenoMouse technology for generating human antibodies to PSMA, as well as has collaboration agreement with Seattle Genetics, Inc. Progenics Pharmaceuticals, Inc. was founded in 1986 and is based in Tarrytown, New York.

57 Employees
Last Reported Date: 03/16/15
Founded in 1986

progenics pharmaceuticals (PGNX) Top Compensated Officers

Chief Executive Officer, Director and Member ...
Total Annual Compensation: $535.6K
Principal Financial Officer, Principal Accoun...
Total Annual Compensation: $279.6K
Executive Vice President of Medical Affairs
Total Annual Compensation: $426.5K
Senior Vice President of Manufacturing
Total Annual Compensation: $296.5K
Compensation as of Fiscal Year 2013.

progenics pharmaceuticals (PGNX) Key Developments

Progenics Pharmaceuticals, Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-15-2015 02:20 PM

Progenics Pharmaceuticals, Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-15-2015 02:20 PM. Venue: Westin Grand Central Hotel, New York, New York, United States. Speakers: Mark R. Baker, Chief Executive Officer, Director and Member of Science & Strategy Committee.

Progenics Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014; Reports Impairment Charges for the Fourth Quarter of 2014

Progenics Pharmaceuticals, Inc. announced unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2014. The company reported Fourth quarter revenue resulted in a loss of $0.6 million, primarily from RELISTOR royalty losses due to Salix's plan to accelerate the reduction of wholesaler inventory levels and substantially cease all sales efforts to wholesalers in the fourth quarter of 2014. This compares to revenues of $3.0 million due to RELISTOR royalty income in the fourth quarter of 2013. Operating loss was $12,954,000 against $8,923,000 a year ago. Net loss before income tax benefit was $12,940,000 against $8,913,000 a year ago. Net loss was $12,179,000 or $0.18 per basic and diluted share against $8,551,000 or $0.14 per basic and diluted share a year ago. For the year, the company reported total revenue of $44,377,000 against $7,862,000 a year ago. Operating income was $3,370,000 against operating loss of $42,980,000 a year ago. Net income before income tax benefit was $3,421,000 against net loss before income tax benefit of $42,934,000 a year ago. Net income was $4,410,000 or $0.06 per basic and diluted share against net loss of $42,572,000 or $0.76 per basic and diluted share a year ago. Full year 2014 revenue was up from the prior year, reflecting an increase in collaboration revenue, primarily resulting from the recognition of milestone from Salix, partially offset by decrease in RELISTOR royalty income, compared to 2013. For the quarter, the company reported intangible impairment charges of $2,100,000.

Progenics Pharmaceuticals, Inc., Q4 2014 Earnings Call, Mar 16, 2015

Progenics Pharmaceuticals, Inc., Q4 2014 Earnings Call, Mar 16, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PGNX:US $6.03 USD -0.375

PGNX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CTI BioPharma Corp $1.96 USD +0.01
Genocea Biosciences Inc $12.24 USD -0.26
Inovio Pharmaceuticals Inc $10.35 USD -0.25
Peregrine Pharmaceuticals Inc $1.39 USD -0.045
Rigel Pharmaceuticals Inc $4.88 USD +0.55
View Industry Companies
 

Industry Analysis

PGNX

Industry Average

Valuation PGNX Industry Range
Price/Earnings 99.1x
Price/Sales 10.0x
Price/Book 3.6x
Price/Cash Flow 90.0x
TEV/Sales 7.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PROGENICS PHARMACEUTICALS, please visit www.progenics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.